Title:
オキサリプラチンおよびEGFR阻害剤を用いた処置
Document Type and Number:
Japanese Patent JP2008501650
Kind Code:
A
Abstract:
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and oxaliplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and oxaliplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva(TM)).
More Like This:
Inventors:
Chain, jumpin
Higgins, Brian
Kolinsky, Kenneth
Higgins, Brian
Kolinsky, Kenneth
Application Number:
JP2007513799A
Publication Date:
January 24, 2008
Filing Date:
May 25, 2005
Export Citation:
Assignee:
F. HOFFMANN-LA ROCHE AKTIENGESELLSCHAFT
International Classes:
A61K31/282; A61K31/28; A61K31/4706; A61K31/498; A61K31/517; A61K31/519; A61K31/5377; A61K33/242; A61K33/243; A61K38/50; A61K45/00; A61P35/00; A61P35/02; A61P35/04; A61P43/00; C07D239/74
Other References:
JPN6010031467, Ｃｏｌｏｒｅｃｔａｌ Ｄｉｓｅａｓｅ, 2003, Ｖｏｌ．５ Ｎｏ．ｓｕｐｐｌ．３, ｐｐ．１−９
JPN6010031468, Ｃｌｉｎ． Ｃａｎｃｅｒ Ｒｅｓ．, 2003, Ｖｏｌ．９, ｐｐ．６０９５ｓ−６０９６ｓ
JPN6010031469, Ｃａｎｃｅｒ Ｃｈｅｍｏｔｈｅｒ． Ｐｈａｒｍａｃｏｌ．, 2003, Ｖｏｌ．５２, ｐｐ．４４２−４４８
JPN6010031470, Ｃｌｉｎ． Ｃａｎｃｅｒ Ｒｅｓ．, 2000, Ｖｏｌ．６, ｐｐ．２０５３−２０６３
JPN6010031468, Ｃｌｉｎ． Ｃａｎｃｅｒ Ｒｅｓ．, 2003, Ｖｏｌ．９, ｐｐ．６０９５ｓ−６０９６ｓ
JPN6010031469, Ｃａｎｃｅｒ Ｃｈｅｍｏｔｈｅｒ． Ｐｈａｒｍａｃｏｌ．, 2003, Ｖｏｌ．５２, ｐｐ．４４２−４４８
JPN6010031470, Ｃｌｉｎ． Ｃａｎｃｅｒ Ｒｅｓ．, 2000, Ｖｏｌ．６, ｐｐ．２０５３−２０６３
Attorney, Agent or Firm:
Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe